GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » DanCann Pharma AS (FRA:DAN0) » Definitions » ROE % Adjusted to Book Value

DanCann Pharma AS (FRA:DAN0) ROE % Adjusted to Book Value : -145.75% (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is DanCann Pharma AS ROE % Adjusted to Book Value?

DanCann Pharma AS's ROE % for the quarter that ended in Dec. 2024 was -64.13%. DanCann Pharma AS's PB Ratio for the quarter that ended in Dec. 2024 was 0.44. DanCann Pharma AS's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was -145.75%.


DanCann Pharma AS ROE % Adjusted to Book Value Historical Data

The historical data trend for DanCann Pharma AS's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DanCann Pharma AS ROE % Adjusted to Book Value Chart

DanCann Pharma AS Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROE % Adjusted to Book Value
Get a 7-Day Free Trial - -11.68 -54.22 -409.43 -156.11

DanCann Pharma AS Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,486.33 -101.29 -5.82 -223.62 -145.75

Competitive Comparison of DanCann Pharma AS's ROE % Adjusted to Book Value

For the Drug Manufacturers - Specialty & Generic subindustry, DanCann Pharma AS's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DanCann Pharma AS's ROE % Adjusted to Book Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, DanCann Pharma AS's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where DanCann Pharma AS's ROE % Adjusted to Book Value falls into.


;
;

DanCann Pharma AS ROE % Adjusted to Book Value Calculation

DanCann Pharma AS's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-68.69% / 0.44
=-156.11%

DanCann Pharma AS's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-64.13% / 0.44
=-145.75%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


DanCann Pharma AS ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of DanCann Pharma AS's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


DanCann Pharma AS Business Description

Traded in Other Exchanges
Address
Rugvaenget 5, Ansager, DNK, DK-6823
DanCann Pharma AS is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma is a licensed production and distribution Company. The company is focused on discovering, developing, manufacturing, and commercializing novel cannabinoid therapeutics for a broad range of diseases.

DanCann Pharma AS Headlines

No Headlines